Thursday, March 28, 2024
ADVT 
Real Estate

ER visits down 25 per cent in early 2020: report

ER visits down 25 per cent in early 2020: report
A new report finds emergency department visits dropped by 25 per cent in the early days of the COVID-19 pandemic.

ER visits down 25 per cent in early 2020: report

UN cautions that virus plasma treatment still experimental

UN cautions that virus plasma treatment still experimental
The World Health Organization on Monday cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy, voicing the concern as a U.S. boost for the treatment has many scientists afraid formal studies will be derailed.

UN cautions that virus plasma treatment still experimental

Pandemic pushes expansion of 'hospital-at-home' treatment

Pandemic pushes expansion of 'hospital-at-home' treatment
As hospitals care for people with COVID-19 and try to keep others from catching the virus, more patients are opting to be treated where they feel safest: at home.

Pandemic pushes expansion of 'hospital-at-home' treatment

Pharmacists can give childhood shots, U.S. officials say

Pharmacists can give childhood shots, U.S. officials say
Pharmacists in all 50 states are now allowed to give childhood vaccinations under a new directive aimed at preventing future outbreaks of measles and other preventable diseases.

Pharmacists can give childhood shots, U.S. officials say

Trail of bubbles leads scientists to new coronavirus clue

Trail of bubbles leads scientists to new coronavirus clue
A doctor checking comatose COVID-19 patients for signs of a stroke instead stumbled onto a new clue about how the virus may harm the lungs -- thanks to a test that used tiny air bubbles and a robot.

Trail of bubbles leads scientists to new coronavirus clue

FDA blocks much-anticipated BioMarin hemophilia gene therapy

FDA blocks much-anticipated BioMarin hemophilia gene therapy
Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company’s potentially game-changing hemophilia A gene therapy over concerns it might not really be a one-and-done lifetime treatment.

FDA blocks much-anticipated BioMarin hemophilia gene therapy